Journal article
RAD51 and Breast Cancer Susceptibility: No Evidence for Rare Variant Association in the Breast Cancer Family Registry Study
F Le Calvez-Kelm, J Oliver, F Damiola, N Forey, N Robinot, G Durand, C Voegele, MP Vallée, G Byrnes, undefined Breast Cancer Family Registry, JL Hopper, MC Southey, IL Andrulis, EM John, SV Tavtigian, F Lesueur
Plos One | PUBLIC LIBRARY SCIENCE | Published : 2012
Abstract
Background: Although inherited breast cancer has been associated with germline mutations in genes that are functionally involved in the DNA homologous recombination repair (HRR) pathway, including BRCA1, BRCA2, TP53, ATM, BRIP1, CHEK2 and PALB2, about 70% of breast cancer heritability remains unexplained. Because of their critical functions in maintaining genome integrity and already well-established associations with breast cancer susceptibility, it is likely that additional genes involved in the HRR pathway harbor sequence variants associated with increased risk of breast cancer. RAD51 plays a central biological function in DNA repair and despite the fact that rare, likely dysfunctional va..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
This work was supported by the National Cancer Institute (NCI), National Institutes of Health (NIH) grant R01 CA121245. The Breast Cancer Family Registry (BCFR) was supported by the NIH under RFA-CA-06-503 and through cooperative agreements with members of the BCFR and Principal Investigators, including Cancer Care Ontario (U01 CA69467), the Cancer Prevention Institute of California (U01 CA69417) and the University of Melbourne (U01 CA69638). The content of this manuscript does not necessarily reflect the views or policies of the NCI or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the United States Government or the BCFR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.